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other countries. RESULTS: In terms of price cuts, the new PPRS is a continuation of 
previous schemes encompassing a 6–7% reduction. Price modulation and proﬁt con-
trols remained unchanged. However, ﬂexible pricing, which encourages companies to 
initially set lower prices to gain approval and increases prices as more evidence of 
effectiveness emerges, has been introduced. The most important difference concerns 
the introduction of PASs, which build on the idea of risk-sharing. Velcade and Lucentis 
provide useful examples of different approaches: the former deﬁning risk in terms of 
“patient response” (outcomes-based) and the latter according to treatment utilisation 
(ﬁnancial-based). Both schemes continue to be active. CONCLUSIONS: The new 
PPRS signiﬁes an important shift in the UK policy framework. The introduction of 
PASs raises issues about scheme implementation and how risk should be measured 
and tracked overtime. The progress of this initiative will shape the renegotiation 
of the next PPRS and the setting of future priorities. However, it is likely that 
“value-based pricing”—however deﬁned and understood—will continue to gain 
momentum.
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OBJECTIVES: Several studies forecasting health care spending predict continuously 
increasing expenses due to at least three different factors; ageing, technical progress, 
and increasing prices. The aim of this study is to identify the effects of inﬂuencing 
factors on the German oncology related expenditures on prescribed drugs (OREPD) 
considering predictor variables such as elderly (65 years and older) population 
(POP65), two pharmaceutical innovation proxies (product age [LC] and novelty 
[NEW]), parallel trade (PI), logarithmized prices (PRICE), and relevant health care 
reforms (REFORM) of oncology related ATC classes (ATC). METHODS: A Random 
Coefﬁcient Mixed Model is implemented to explore multivariate longitudinal/repeated 
observation data excluding between-drug variation from error, providing more efﬁ-
cient estimators by separating aging (changes over time within drugs) from cohort 
(differences between drugs at baseline) effects. RESULTS: The analyses including 
logarithmized German monthly prescription data for a 5 years period (2003–2007) 
covering all relevant ATC classes related to cancer treatment show highly signiﬁcant 
effects within a ﬁxed effects model for LC(0.0043,p  0.0001), NEW(1.6264,p  
0.0001), PI(2.1314,p  0.0001), and POP65(2.19E-7,p  0.0001). The random 
effect model also provides highly signiﬁcant results for the drug speciﬁc INTERCEPT 
(37.0127,p  0.0001), time-variant effects of REFORM(0.0005,p  0.0001), and 
PRICE(1.3300,p0.0001). CONCLUSIONS: The results show increasing oncology 
related prescriptions with increasing manufactures (respectively decreasing parallel 
importers) in the market and the longer the drugs are available in the market. It seems 
that prescriptions are inﬂuenced by a certain awareness and trust in new drugs. The 
newer the drug the less it’s prescribed which might be a consequence of risk adversity 
due to lacking experienced successful treatments. Decreasing prescriptions with 
increasing elderly population is somewhat counterintuitive but might be caused by 
multimorbidity and difﬁculties due to adverse effects of multiple prescriptions. The 
intercept indicates a high baseline and over time reforms are not successful in cost 
containment. Additionally, increasing prices lead to increasing oncology related 
prescriptions.
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OBJECTIVES: Studies have shown that the use of high-dose irinotecan in cancer 
therapy is associated with an increased risk for severe neutropenia in UGT1A1 7/7 
genotype patients. The aim of the present study was to evaluate cost-effectiveness of 
UGT1A1 genotyping prior to administration of high-dose irinotecan in second-line 
colorectal cancer treatment. METHODS: UGT1A1 genotyping with subsequent initial 
irinotecan dose reduction or a prophylactic use of G-CSF in UGT1A1 7/7 genotype 
patients was compared to standard therapy in a decision analysis. The effectiveness 
outcome was severe neutropenia occurrence and number of life-years gained. Cost-
effectiveness of UGT1A1 genotyping was calculated separately for patients with 
African, Asian and Caucasian origin due to different UGT1A1 7/7 genotype frequen-
cies. The analysis was performed from the USA health care payer perspective. 
RESULTS: UGT1A1 genotyping in combination with subsequent reduction of initial 
irinotecan dose for UGT1A1 7/7 genotype patients was cost-saving for the population 
of African and Caucasian origin. On the contrary, an incremental cost-effectiveness 
ratio was more than 6 mio USD per LYG for the population of Asian ancestry. Fur-
thermore, UGT1A1 genotyping with subsequent prophylactic use of granulocyte-
colony stimulating factors in UGT1A1 7/7 genotype patients resulted in incremental 
cost-effectiveness ratio above 3 mio USD per life-year gained for all population groups. 
CONCLUSIONS: The use of UGT1A1 genotyping prior to high-dose irinotecan 
therapy could represent a good value for money for certain patient groups.
PCN158
LUXEMBOURG LUNG CANCER PROJECT: POTENTIAL CLINICAL AND 
ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE 
DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES  
IN LUXEMBOURG
Carlson JJ1, Clarke L2, Berchem G3, Schlesser M3, Nelson J4, Ramsey SD4
1University of Washington, Seattle, WA, USA, 2Cornerstone Systems Northwest, Inc, 
Lynden, WA, USA, 3Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg, 
4Fred Hutchinson Cancer Research Center, Seattle, WA, USA
OBJECTIVES: As part of a program using economic evaluation to guide discovery 
efforts in personalized medicine, we evaluated the potential clinical and economic 
impact of biomarker-directed management of patients with single pulmonary nodules 
(SPN) versus current practice in Luxembourg. METHODS: We developed a decision 
analytic model from the payer perspective using data from Luxembourg and neighbor-
ing countries. Decision pathways were based on input from clinical experts and health 
services researchers. The model follows patients from SPN identiﬁcation to death 
comparing standard care (bronchoscopy, CT scans, and FDG PET scans) with bio-
marker-directed evaluation. Endpoints included lung cancers detected, false positive 
and negative tests, life expectancy, and related medical care costs. Threshold analyses 
were performed to assess levels of biomarker performance that would be cost-effective. 
RESULTS: Compared to standard care, biomarker-based management produced an 
average survival beneﬁt of 0.015 years and average cost savings of a1430, dominating 
standard care. The improved life expectancy was primarily the result of identifying 
and treating patients with malignant tumors earlier. The cost savings were primarily 
driven by avoiding costly diagnostic procedures (e.g. FDG PET). In sensitivity analysis, 
test characteristics for bronchoscopy and FDG PET had the largest impact on model 
results. At a sensitivity/speciﬁcity of 0.83/0.83, the biomarker-based strategy was no 
longer more effective than standard care. There was no simultaneous decrease in sen-
sitivity/speciﬁcity that made the biomarker based strategy more costly than standard 
care. Finally, the cost of the biomarker-based test could increase to a1530 with the 
strategy remaining less costly than standard care. CONCLUSIONS: Biomarkers have 
the potential to improve the management of patients diagnosed with SPN’s in Lux-
embourg. At a sensitivity/speciﬁcity of 0.95/0.95, biomarker-directed management 
could improve outcomes and reduce costs for the Luxembourg health system. Bio-
marker development efforts at this and other strategic points along the lung cancer 
treatment pathway are underway.
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OBJECTIVES: Metastasectomy in patients with metastatic colorectal cancer (mCRC) 
is the best option to achieve long-term survival and offers the only chance for cure. 
Increasing the number of resectable patients is therefore a medical treatment goal. This 
study examines the trend over time in metastasectomy and pre-surgery chemo- and 
biologic therapy in newly diagnosed mCRC patients. METHODS: Using a large, U.S. 
medical claims database from a national commercially-insured population, we identi-
ﬁed patients with newly diagnosed mCRC between 2001 and 2005. Metastasectomy 
rates by anatomic location were assessed for all mCRC patients during one year after 
mCRC diagnosis. Chemotherapy and/or biological therapy within 90 days prior to 
the date of metastasectomy was evaluated. RESULTS: A total of 1785 newly diag-
nosed mCRC patients were identiﬁed; of which 327 patients (18.3%) received metas-
tasectomy within one year after mCRC diagnosis. This included 70 patients (3.9%) 
who were not initially resected but had metastasectomy following chemo- and/or 
biologic therapy. From 2001 to 2005, the most common surgery site was the liver 
(ranged 13.9%–16.7%), followed by the lung (2.3% to 4.9%) and pelvic resection 
(0.0%–0.5%). The percentage of patients who were not initially resected and had 
metastasectomy after receiving chemo- and/or biologic therapy increased from 2.9% 
in 2001 to 5.6% in 2005. Among patients who received pre-surgery chemo- and/or 
biologic therapy, the percentage of receiving biologic therapy increased rapidly in 
2004–2005 from 35.0% to 77.3%. CONCLUSIONS: The proportion of patients with 
mCRC undergoing metastasectomy increased over time and the percentage of patients 
who were not initially resected and had metastasectomy after receiving chemo- and/or 
biologic therapy almost doubled during the study period.
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OBJECTIVES: Modern targeted anticancer therapy introduces powerful treatment 
modality in cancer care. However, due to its cost the overall number of administra-
tions has to be monitored and prospectively planned. The objective of this work is to 
design, apply and verify a multi-component statistical model that employs data from 
population records, clinical registries and data provided by an expert panel to predict 
the number of cancer patients who would be probably treated with targeted therapy 
in the following years. METHODS: Computations are primarily based on data from 
the Czech National Cancer Registry, which covers the entire population since 1977. 
The modelling process has two steps. In the ﬁrst step, number of potentially treated 
